series-c-plus
Stage
1
Investors
About
Y-mAbs Therapeutics develops and commercializes antibody-based and radioimmunotherapy treatments targeting difficult-to-treat cancers, including its marketed product DANYELZA (naxitamab) for high-risk neuroblastoma.
Explore Y-mAbs Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.